Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib) — Medica

Graft-Versus-Host Disease, Chronic

Initial criteria

  • age ≥ 12 years
  • patient has tried one conventional systemic treatment for graft-versus-host disease

Approval duration

1 year